{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,20]],"date-time":"2026-10-20T18:27:57Z","timestamp":1792520877921,"version":"4.5.0"},"reference-count":143,"publisher":"Springer Science and Business Media LLC","issue":"3","license":[{"start":{"date-parts":[[2019,9,1]],"date-time":"2019-09-01T00:00:00Z","timestamp":1567296000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2019,9,3]],"date-time":"2019-09-03T00:00:00Z","timestamp":1567468800000},"content-version":"vor","delay-in-days":2,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Cancer Metastasis Rev"],"published-print":{"date-parts":[[2019,9]]},"DOI":"10.1007\/s10555-019-09807-3","type":"journal-article","created":{"date-parts":[[2019,9,3]],"date-time":"2019-09-03T07:05:28Z","timestamp":1567494328000},"page":"417-430","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":41,"title":["Proteolytic chemokine cleavage as a regulator of lymphocytic infiltration in solid tumors"],"prefix":"10.1007","volume":"38","author":[{"given":"Holger","family":"Bronger","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Viktor","family":"Magdolen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Peter","family":"Goettig","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tobias","family":"Dreyer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2019,9,3]]},"reference":[{"issue":"2","key":"9807_CR1","first-page":"125","volume":"1","author":"EE Tyzzer","year":"1916","unstructured":"Tyzzer, E. E. (1916). Tumor immunity. American Journal of Cancer Research, 1(2), 125\u2013156.","journal-title":"American Journal of Cancer Research"},{"key":"9807_CR2","doi-asserted-by":"publisher","first-page":"829","DOI":"10.3389\/fimmu.2017.00829","volume":"8","author":"WK Decker","year":"2017","unstructured":"Decker, W. K., da Silva, R. F., Sanabria, M. H., Angelo, L. S., Guimaraes, F., Burt, B. M., et al. (2017). Cancer immunotherapy: historical perspective of a clinical revolution and emerging preclinical animal models. Frontiers in Immunology, 8, 829.","journal-title":"Frontiers in Immunology"},{"issue":"3","key":"9807_CR3","doi-asserted-by":"publisher","first-page":"203","DOI":"10.1056\/NEJMoa020177","volume":"348","author":"L Zhang","year":"2003","unstructured":"Zhang, L., Conejo-Garcia, J. R., Katsaros, D., Gimotty, P. A., Massobrio, M., Regnani, G., Makrigiannakis, A., Gray, H., Schlienger, K., Liebman, M. N., Rubin, S. C., & Coukos, G. (2003). Intratumoral T cells, recurrence, and survival in epithelial ovarian cancer. New England Journal of Medicine, 348(3), 203\u2013213.","journal-title":"New England Journal of Medicine"},{"issue":"Pt 2","key":"9807_CR4","doi-asserted-by":"publisher","first-page":"16","DOI":"10.1016\/j.semcancer.2017.10.003","volume":"52","author":"MV Dieci","year":"2018","unstructured":"Dieci, M. V., Radosevic-Robin, N., Fineberg, S., van den Eynden, G., Ternes, N., Penault-Llorca, F., et al. (2018). Update on tumor-infiltrating lymphocytes (TILs) in breast cancer, including recommendations to assess TILs in residual disease after neoadjuvant therapy and in carcinoma in situ: a report of the international immuno-oncology biomarker working group on Bre. Seminars in Cancer Biology, 52(Pt 2), 16\u201325.","journal-title":"Seminars in Cancer Biology"},{"issue":"10135","key":"9807_CR5","doi-asserted-by":"publisher","first-page":"2128","DOI":"10.1016\/S0140-6736(18)30789-X","volume":"391","author":"F Pages","year":"2018","unstructured":"Pages, F., Mlecnik, B., Marliot, F., Bindea, G., Ou, F. S., Bifulco, C., et al. (2018). International validation of the consensus immunoscore for the classification of colon cancer: a prognostic and accuracy study. Lancet, 391(10135), 2128\u20132139.","journal-title":"Lancet"},{"issue":"4","key":"9807_CR6","doi-asserted-by":"publisher","first-page":"298","DOI":"10.1038\/nrc3245","volume":"12","author":"WH Fridman","year":"2012","unstructured":"Fridman, W. H., Pages, F., Sautes-Fridman, C., & Galon, J. (2012). The immune contexture in human tumours: impact on clinical outcome. Nature Reviews. Cancer, 12(4), 298\u2013306.","journal-title":"Nature Reviews. Cancer"},{"issue":"12","key":"9807_CR7","doi-asserted-by":"publisher","first-page":"717","DOI":"10.1038\/nrclinonc.2017.101","volume":"14","author":"WH Fridman","year":"2017","unstructured":"Fridman, W. H., Zitvogel, L., Sautes-Fridman, C., & Kroemer, G. (2017). The immune contexture in cancer prognosis and treatment. Nature Reviews. Clinical Oncology, 14(12), 717\u2013734.","journal-title":"Nature Reviews. Clinical Oncology"},{"issue":"36","key":"9807_CR8","doi-asserted-by":"publisher","first-page":"298","DOI":"10.14694\/EDBK_156572","volume":"35","author":"V Velcheti","year":"2016","unstructured":"Velcheti, V., & Schalper, K. (2016). Basic overview of current immunotherapy approaches in cancer. American Society of Clinical Oncology Educational Book, 35(36), 298\u2013308.","journal-title":"American Society of Clinical Oncology Educational Book"},{"issue":"10087","key":"9807_CR9","doi-asserted-by":"publisher","first-page":"2415","DOI":"10.1016\/S0140-6736(16)32417-5","volume":"389","author":"S Loibl","year":"2017","unstructured":"Loibl, S., & Gianni, L. (2017). HER2-positive breast cancer. The Lancet, 389(10087), 2415\u20132429.","journal-title":"The Lancet"},{"issue":"17","key":"9807_CR10","doi-asserted-by":"publisher","first-page":"1974","DOI":"10.1200\/JCO.2014.59.4358","volume":"33","author":"MA Postow","year":"2015","unstructured":"Postow, M. A., Callahan, M. K., & Wolchok, J. D. (2015). Immune checkpoint blockade in cancer therapy. Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology, 33(17), 1974\u20131982.","journal-title":"Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology"},{"issue":"11","key":"9807_CR11","doi-asserted-by":"publisher","first-page":"895","DOI":"10.1158\/2326-6066.CIR-16-0197","volume":"4","author":"L Galluzzi","year":"2016","unstructured":"Galluzzi, L., Zitvogel, L., & Kroemer, G. (2016). Immunological mechanisms underneath the efficacy of cancer therapy. Cancer Immunology Research, 4(11), 895\u2013902.","journal-title":"Cancer Immunology Research"},{"issue":"9","key":"9807_CR12","doi-asserted-by":"publisher","first-page":"2159","DOI":"10.1158\/0008-5472.CAN-11-3538","volume":"72","author":"J-P Abastado","year":"2012","unstructured":"Abastado, J.-P. (2012). The next challenge in cancer immunotherapy: controlling T-cell traffic to the tumor. Cancer Research, 72(9), 2159\u20132161.","journal-title":"Cancer Research"},{"issue":"5","key":"9807_CR13","doi-asserted-by":"publisher","first-page":"522","DOI":"10.1158\/2159-8290.CD-13-0985","volume":"4","author":"I Melero","year":"2014","unstructured":"Melero, I., Rouzaut, A., Motz, G. T., & Coukos, G. (2014). T-cell and NK-cell infiltration into solid tumors: a key limiting factor for efficacious cancer immunotherapy. Cancer Discovery, 4(5), 522\u2013526.","journal-title":"Cancer Discovery"},{"issue":"2","key":"9807_CR14","doi-asserted-by":"publisher","first-page":"527","DOI":"10.1016\/j.bbcan.2017.10.003","volume":"1868","author":"D de Melo Gagliato","year":"2017","unstructured":"de Melo Gagliato, D., Cortes, J., Curigliano, G., Loi, S., Denkert, C., Perez-Garcia, J., & Holgado, E. (2017). Tumor-infiltrating lymphocytes in breast cancer and implications for clinical practice. Biochimica Et Biophysica Acta. Reviews on Cancer, 1868(2), 527\u2013537.","journal-title":"Biochimica Et Biophysica Acta. Reviews on Cancer"},{"issue":"3","key":"9807_CR15","doi-asserted-by":"publisher","first-page":"197","DOI":"10.1038\/s41573-018-0007-y","volume":"18","author":"J Galon","year":"2019","unstructured":"Galon, J., & Bruni, D. (2019). Approaches to treat immune hot, altered and cold tumours with combination immunotherapies. Nature Reviews. Drug Discovery, 18(3), 197\u2013218.","journal-title":"Nature Reviews. Drug Discovery"},{"issue":"5","key":"9807_CR16","doi-asserted-by":"publisher","first-page":"705","DOI":"10.1016\/j.immuni.2012.05.008","volume":"36","author":"A Zlotnik","year":"2012","unstructured":"Zlotnik, A., & Yoshie, O. (2012). The chemokine superfamily revisited. Immunity, 36(5), 705\u2013716.","journal-title":"Immunity"},{"issue":"9","key":"9807_CR17","doi-asserted-by":"publisher","first-page":"559","DOI":"10.1038\/nri.2017.49","volume":"17","author":"N Nagarsheth","year":"2017","unstructured":"Nagarsheth, N., Wicha, M. S., & Zou, W. (2017). Chemokines in the cancer microenvironment and their relevance in cancer immunotherapy. Nature Reviews Immunology, 17(9), 559\u2013572.","journal-title":"Nature Reviews Immunology"},{"issue":"6\u20137","key":"9807_CR18","doi-asserted-by":"publisher","first-page":"1185","DOI":"10.1016\/j.biocel.2007.12.009","volume":"40","author":"M Wolf","year":"2008","unstructured":"Wolf, M., Albrecht, S., & M\u00e4rki, C. (2008). Proteolytic processing of chemokines: implications in physiological and pathological conditions. The International Journal of Biochemistry & Cell Biology, 40(6\u20137), 1185\u20131198.","journal-title":"The International Journal of Biochemistry & Cell Biology"},{"issue":"8","key":"9807_CR19","doi-asserted-by":"publisher","first-page":"850","DOI":"10.1038\/ni.3201","volume":"16","author":"Rosa Barreira da Silva","year":"2015","unstructured":"Barreira da Silva, R., Laird, M. E., Yatim, N., Fiette, L., Molly, A., Ingersoll, M., Albert, L., et al. (2015). Dipeptidylpeptidase 4 inhibition enhances lymphocyte trafficking, improving both naturally occurring tumor immunity and immunotherapy. Nature Immunology, 8(16), 850\u2013858.","journal-title":"Nature Immunology"},{"issue":"6","key":"9807_CR20","doi-asserted-by":"publisher","first-page":"1498","DOI":"10.1016\/j.immuni.2019.04.010","volume":"50","author":"MT Chow","year":"2019","unstructured":"Chow, M. T., Ozga, A. J., Servis, R. L., Frederick, D. T., Lo, J. A., Fisher, D. E., Freeman, G. J., Boland, G. M., & Luster, A. D. (2019). Intratumoral activity of the CXCR3 chemokine system is required for the efficacy of anti-PD-1 therapy. Immunity, 50(6), 1498\u20131512 e5.","journal-title":"Immunity"},{"issue":"1","key":"9807_CR21","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/j.immuni.2013.07.012","volume":"39","author":"DS Chen","year":"2013","unstructured":"Chen, D. S., & Mellman, I. (2013). Oncology meets immunology: the cancer-immunity cycle. Immunity, 39(1), 1\u201310.","journal-title":"Immunity"},{"key":"9807_CR22","doi-asserted-by":"publisher","first-page":"1970","DOI":"10.3389\/fimmu.2017.01970","volume":"8","author":"M Metzemaekers","year":"2017","unstructured":"Metzemaekers, M., Vanheule, V., Janssens, R., Struyf, S., & Proost, P. (2017). Overview of the mechanisms that may contribute to the non-redundant activities of interferon-inducible CXC chemokine receptor 3 ligands. Frontiers in Immunology, 8, 1970.","journal-title":"Frontiers in Immunology"},{"issue":"3","key":"9807_CR23","doi-asserted-by":"publisher","first-page":"469","DOI":"10.1590\/S1679-45082015RB3438","volume":"13","author":"DCT Palomino","year":"2015","unstructured":"Palomino, D. C. T., & Marti, L. C. (2015). Chemokines and immunity. Einstein (S\u00e3o Paulo), 13(3), 469\u2013473.","journal-title":"Einstein (S\u00e3o Paulo)"},{"key":"9807_CR24","doi-asserted-by":"publisher","first-page":"379","DOI":"10.3389\/fimmu.2019.00379","volume":"10","author":"VM Poeta","year":"2019","unstructured":"Poeta, V. M., Massara, M., Capucetti, A., & Bonecchi, R. (2019). Chemokines and chemokine receptors: new targets for cancer immunotherapy. Frontiers in Immunology, 10, 379.","journal-title":"Frontiers in Immunology"},{"issue":"Suppl 2","key":"9807_CR25","first-page":"ii84","volume":"63","author":"B Moser","year":"2004","unstructured":"Moser, B., & Willimann, K. (2004). Chemokines: role in inflammation and immune surveillance. Annals of the Rheumatic Diseases, 63(Suppl 2), ii84\u2013ii89.","journal-title":"Annals of the Rheumatic Diseases"},{"issue":"11","key":"9807_CR26","doi-asserted-by":"publisher","first-page":"2563","DOI":"10.1016\/j.bbamcr.2014.05.014","volume":"1843","author":"MD Turner","year":"2014","unstructured":"Turner, M. D., Nedjai, B., Hurst, T., & Pennington, D. J. (2014). Cytokines and chemokines: At the crossroads of cell signalling and inflammatory disease. Biochimica et Biophysica Acta, Molecular Cell Research, 1843(11), 2563\u20132582.","journal-title":"Biochimica et Biophysica Acta, Molecular Cell Research"},{"issue":"4","key":"9807_CR27","doi-asserted-by":"publisher","first-page":"615","DOI":"10.1111\/j.0022-202X.2005.23841.x","volume":"125","author":"C Esche","year":"2005","unstructured":"Esche, C., Stellato, C., & Beck, L. A. (2005). Chemokines: key players in innate and adaptive immunity. The Journal of Investigative Dermatology, 125(4), 615\u2013628.","journal-title":"The Journal of Investigative Dermatology"},{"issue":"1","key":"9807_CR28","doi-asserted-by":"publisher","first-page":"659","DOI":"10.1146\/annurev-immunol-032713-120145","volume":"32","author":"JW Griffith","year":"2014","unstructured":"Griffith, J. W., Sokol, C. L., & Luster, A. D. (2014). Chemokines and chemokine receptors: positioning cells for host defense and immunity. Annual Review of Immunology, 32(1), 659\u2013702.","journal-title":"Annual Review of Immunology"},{"key":"9807_CR29","first-page":"59","volume":"341","author":"A Dimberg","year":"2010","unstructured":"Dimberg, A. (2010). Chemokines in angiogenesis. Current Topics in Microbiology and Immunology, 341, 59\u201380.","journal-title":"Current Topics in Microbiology and Immunology"},{"issue":"5","key":"9807_CR30","doi-asserted-by":"publisher","first-page":"755","DOI":"10.1160\/TH07-01-0040","volume":"97","author":"B Mehrad","year":"2007","unstructured":"Mehrad, B., Keane, M. P., & Strieter, R. M. (2007). Chemokines as mediators of angiogenesis. Thrombosis and Haemostasis, 97(5), 755\u2013762.","journal-title":"Thrombosis and Haemostasis"},{"issue":"3","key":"9807_CR31","doi-asserted-by":"publisher","first-page":"907","DOI":"10.1172\/JCI40645","volume":"120","author":"J Eberlein","year":"2010","unstructured":"Eberlein, J., Nguyen, T. T., Victorino, F., Golden-Mason, L., Rosen, H. R., & Homann, D. (2010). Comprehensive assessment of chemokine expression profiles by flow cytometry. Journal of Clinical Investigation, 120(3), 907\u2013923.","journal-title":"Journal of Clinical Investigation"},{"issue":"12","key":"9807_CR32","doi-asserted-by":"publisher","first-page":"243","DOI":"10.1186\/gb-2006-7-12-243","volume":"7","author":"A Zlotnik","year":"2006","unstructured":"Zlotnik, A., Yoshie, O., & Nomiyama, H. (2006). The chemokine and chemokine receptor superfamilies and their molecular evolution. Genome Biology, 7(12), 243.","journal-title":"Genome Biology"},{"issue":"1\u20132","key":"9807_CR33","doi-asserted-by":"publisher","first-page":"2","DOI":"10.1016\/j.imlet.2012.04.015","volume":"145","author":"A Mortier","year":"2012","unstructured":"Mortier, A., Van Damme, J., & Proost, P. (2012). Overview of the mechanisms regulating chemokine activity and availability. Immunology Letters, 145(1\u20132), 2\u20139.","journal-title":"Immunology Letters"},{"issue":"11","key":"9807_CR34","doi-asserted-by":"publisher","first-page":"815","DOI":"10.1038\/nri3544","volume":"13","author":"RJB Nibbs","year":"2013","unstructured":"Nibbs, R. J. B., & Graham, G. J. (2013). Immune regulation by atypical chemokine receptors. Nature Reviews Immunology, 13(11), 815\u2013829.","journal-title":"Nature Reviews Immunology"},{"issue":"16","key":"9807_CR35","doi-asserted-by":"publisher","first-page":"2944","DOI":"10.1111\/febs.14466","volume":"285","author":"CE Hughes","year":"2018","unstructured":"Hughes, C. E., & Nibbs, R. J. B. (2018). A guide to chemokines and their receptors. FEBS Journal, 285(16), 2944\u20132971.","journal-title":"FEBS Journal"},{"key":"9807_CR36","doi-asserted-by":"publisher","first-page":"95","DOI":"10.12688\/f1000research.13130.1","volume":"7","author":"DF Legler","year":"2018","unstructured":"Legler, D. F., & Thelen, M. (2018). New insights in chemokine signaling. F1000Research, 7, 95.","journal-title":"F1000Research"},{"issue":"JUN","key":"9807_CR37","first-page":"277","volume":"5","author":"A Steen","year":"2014","unstructured":"Steen, A., Larsen, O., Thiele, S., & Rosenkilde, M. M. (2014). Biased and G protein-independent signaling of chemokine receptors. Frontiers in Immunology, 5(JUN), 277.","journal-title":"Frontiers in Immunology"},{"issue":"10","key":"9807_CR38","doi-asserted-by":"publisher","first-page":"E2088","DOI":"10.3390\/ijms18102088","volume":"18","author":"MC Miller","year":"2017","unstructured":"Miller, M. C., & Mayo, K. H. (2017). Chemokines from a structural perspective. International Journal of Molecular Sciences, 18(10), E2088.","journal-title":"International Journal of Molecular Sciences"},{"issue":"2","key":"9807_CR39","doi-asserted-by":"publisher","first-page":"121","DOI":"10.1016\/S1074-7613(00)80165-X","volume":"12","author":"A Zlotnik","year":"2000","unstructured":"Zlotnik, A., & Yoshie, O. (2000). Chemokines: a new classification system and their role in immunity. Immunity, 12(2), 121\u2013127.","journal-title":"Immunity"},{"issue":"5","key":"9807_CR40","doi-asserted-by":"publisher","first-page":"325","DOI":"10.1007\/s10540-006-9025-9","volume":"26","author":"L Rajagopalan","year":"2006","unstructured":"Rajagopalan, L., & Rajarathnam, K. (2006). Structural basis of chemokine receptor function\u2013a model for binding affinity and ligand selectivity. Bioscience Reports, 26(5), 325\u2013339.","journal-title":"Bioscience Reports"},{"issue":"10","key":"9807_CR41","doi-asserted-by":"publisher","first-page":"3464","DOI":"10.1074\/jbc.RA118.006535","volume":"294","author":"J Sanchez","year":"2019","unstructured":"Sanchez, J., Huma e, Z., Lane, J. R., Liu, X., Bridgford, J. L., Payne, R. J., et al. (2019). Evaluation and extension of the two-site, two-step model for binding and activation of the chemokine receptor CCR1. The Journal of Biological Chemistry, 294(10), 3464\u20133475.","journal-title":"The Journal of Biological Chemistry"},{"issue":"3","key":"9807_CR42","doi-asserted-by":"publisher","first-page":"E70","DOI":"10.3390\/ph10030070","volume":"10","author":"AEI Proudfoot","year":"2017","unstructured":"Proudfoot, A. E. I., Johnson, Z., Bonvin, P., & Handel, T. M. (2017). Glycosaminoglycan interactions with chemokines add complexity to a complex system. Pharmaceuticals, 10(3), E70.","journal-title":"Pharmaceuticals"},{"issue":"45","key":"9807_CR43","doi-asserted-by":"publisher","first-page":"27348","DOI":"10.1074\/jbc.270.45.27348","volume":"270","author":"RM Strieter","year":"1995","unstructured":"Strieter, R. M., Polverini, P. J., Kunkel, S. L., Arenberg, D. A., Burdick, M. D., Kasper, J., Dzuiba, J., van Damme, J., Walz, A., Marriott, D., Chan, S. Y., Roczniak, S., & Shanafelt, A. B. (1995). The functional role of the ELR motif in CXC chemokine-mediated angiogenesis. Journal of Biological Chemistry, 270(45), 27348\u201327357.","journal-title":"Journal of Biological Chemistry"},{"issue":"2","key":"9807_CR44","first-page":"287","volume":"1836","author":"C Billottet","year":"2013","unstructured":"Billottet, C., Quemener, C., & Bikfalvi, A. (2013). CXCR3, a double-edged sword in tumor progression and angiogenesis. Biochimica et Biophysica Acta, 1836(2), 287\u2013295.","journal-title":"Biochimica et Biophysica Acta"},{"issue":"10","key":"9807_CR45","doi-asserted-by":"publisher","first-page":"6234","DOI":"10.4049\/jimmunol.173.10.6234","volume":"173","author":"JE Ehlert","year":"2004","unstructured":"Ehlert, J. E., Addison, C. A., Burdick, M. D., Kunkel, S. L., & Strieter, R. M. (2004). Identification and partial characterization of a variant of human CXCR3 generated by posttranscriptional exon skipping. The Journal of Immunology, 173(10), 6234\u20136240.","journal-title":"The Journal of Immunology"},{"issue":"20","key":"9807_CR46","doi-asserted-by":"publisher","first-page":"8437","DOI":"10.1158\/0008-5472.CAN-08-1440","volume":"68","author":"M Wendel","year":"2008","unstructured":"Wendel, M., Galani, I. E., Suri-Payer, E., & Cerwenka, A. (2008). Natural killer cell accumulation in tumors is dependent on IFN-gamma and CXCR3 ligands. Cancer Research, 68(20), 8437\u20138445.","journal-title":"Cancer Research"},{"issue":"2","key":"9807_CR47","doi-asserted-by":"publisher","first-page":"207","DOI":"10.1038\/icb.2010.158","volume":"89","author":"JR Groom","year":"2011","unstructured":"Groom, J. R., & Luster, A. D. (2011). CXCR3 ligands: redundant, collaborative and antagonistic functions. Immunology and Cell Biology, 89(2), 207\u2013215.","journal-title":"Immunology and Cell Biology"},{"issue":"4","key":"9807_CR48","doi-asserted-by":"publisher","first-page":"707","DOI":"10.1124\/mol.59.4.707","volume":"59","author":"MA Cox","year":"2001","unstructured":"Cox, M. A., Jenh, C. H., Gonsiorek, W., Fine, J., Narula, S. K., Zavodny, P. J., & Hipkin, R. W. (2001). Human interferon-inducible 10-kDa protein and human interferon-inducible T cell alpha chemoattractant are allotopic ligands for human CXCR3: differential binding to receptor states. Molecular Pharmacology, 59(4), 707\u2013715.","journal-title":"Molecular Pharmacology"},{"issue":"29","key":"9807_CR49","doi-asserted-by":"publisher","first-page":"30219","DOI":"10.1074\/jbc.M403595200","volume":"279","author":"RA Colvin","year":"2004","unstructured":"Colvin, R. A., Campanella, G. S. V., Sun, J., & Luster, A. D. (2004). Intracellular domains of CXCR3 that mediate CXCL9, CXCL10, and CXCL11 function. Journal of Biological Chemistry, 279(29), 30219\u201330227.","journal-title":"Journal of Biological Chemistry"},{"issue":"5","key":"9807_CR50","doi-asserted-by":"publisher","first-page":"2009","DOI":"10.1172\/JCI71951","volume":"124","author":"Y Zohar","year":"2014","unstructured":"Zohar, Y., Wildbaum, G., Novak, R., Salzman, A. L., Thelen, M., Alon, R., Barsheshet, Y., Karp, C. L., & Karin, N. (2014). CXCL11-dependent induction of FOXP3-negative regulatory T cells suppresses autoimmune encephalomyelitis. Journal of Clinical Investigation, 124(5), 2009\u20132022.","journal-title":"Journal of Clinical Investigation"},{"issue":"6","key":"9807_CR51","doi-asserted-by":"publisher","first-page":"1091","DOI":"10.1016\/j.immuni.2012.08.016","volume":"37","author":"JR Groom","year":"2012","unstructured":"Groom, J. R., Richmond, J., Murooka, T. T., Sorensen, E. W., Sung, J. H., Bankert, K., von Andrian, U. H., Moon, J. J., Mempel, T. R., & Luster, A. D. (2012). CXCR3 chemokine receptor-ligand interactions in the lymph node optimize CD4+ T helper 1 cell differentiation. Immunity, 37(6), 1091\u20131103.","journal-title":"Immunity"},{"issue":"5","key":"9807_CR52","doi-asserted-by":"publisher","first-page":"620","DOI":"10.1016\/j.yexcr.2010.12.017","volume":"317","author":"JR Groom","year":"2012","unstructured":"Groom, J. R., & Luster, A. D. (2012). CXCR3 in T cell function. Experimental Cell Research, 317(5), 620\u2013631.","journal-title":"Experimental Cell Research"},{"key":"9807_CR53","doi-asserted-by":"publisher","first-page":"395","DOI":"10.1007\/s00005-014-0275-0","volume":"62","author":"P Wojdasiewicz","year":"2014","unstructured":"Wojdasiewicz, P., Poniatowski, \u0141. A., Kotela, A., Deszczy\u0144ski, J., Kotela, I., & Szukiewicz, D. (2014). The chemokine CX3CL1 (fractalkine) and its receptor CX3CR1: occurrence and potential role in osteoarthritis. Archivum Immunologiae et Therapiae Experimentalis, 62, 395\u2013403.","journal-title":"Archivum Immunologiae et Therapiae Experimentalis"},{"issue":"6617","key":"9807_CR54","doi-asserted-by":"publisher","first-page":"640","DOI":"10.1038\/385640a0","volume":"385","author":"JF Bazan","year":"1997","unstructured":"Bazan, J. F., Bacon, K. B., Hardiman, G., Wang, W., Soo, K., Rossi, D., Greaves, D. R., Zlotnik, A., & Schall, T. J. (1997). A new class of membrane-bound chemokine with a CX3C motif. Nature, 385(6617), 640\u2013644.","journal-title":"Nature"},{"issue":"22","key":"9807_CR55","doi-asserted-by":"publisher","first-page":"e156","DOI":"10.1182\/blood-2011-04-348946","volume":"118","author":"K-W Kim","year":"2011","unstructured":"Kim, K.-W., Vallon-Eberhard, A., Zigmond, E., Farache, J., Shezen, E., Shakhar, G., Ludwig, A., Lira, S. A., & Jung, S. (2011). In vivo structure\/function and expression analysis of the CX3C chemokine fractalkine. Blood, 118(22), e156\u2013e167.","journal-title":"Blood"},{"issue":"4","key":"9807_CR56","doi-asserted-by":"publisher","first-page":"521","DOI":"10.1016\/S0092-8674(00)80438-9","volume":"91","author":"T Imai","year":"1997","unstructured":"Imai, T., Hieshima, K., Haskell, C., Baba, M., Nagira, M., Nishimura, M., Kakizaki, M., Takagi, S., Nomiyama, H., Schall, T. J., & Yoshie, O. (1997). Identification and molecular characterization of fractalkine receptor CX3CR1, which mediates both leukocyte migration and adhesion. Cell, 91(4), 521\u2013530.","journal-title":"Cell"},{"issue":"4","key":"9807_CR57","doi-asserted-by":"publisher","first-page":"611","DOI":"10.1074\/mcp.M600341-MCP200","volume":"6","author":"RA Dean","year":"2007","unstructured":"Dean, R. A., & Overall, C. M. (2007). Proteomics discovery of metalloproteinase substrates in the cellular context by iTRAQ labeling reveals a diverse MMP-2 substrate degradome. Molecular & Cellular Proteomics : MCP, 6(4), 611\u2013623.","journal-title":"Molecular & Cellular Proteomics : MCP"},{"key":"9807_CR58","doi-asserted-by":"publisher","first-page":"1173","DOI":"10.1242\/bio.20149845","volume":"3","author":"MA Ostuni","year":"2014","unstructured":"Ostuni, M. A., Guellec, J., Hermand, P., Durand, P., Combadiere, C., Pincet, F., & Deterre, P. (2014). CX3CL1, a chemokine finely tuned to adhesion: critical roles of the stalk glycosylation and the membrane domain. Biology Open, 3, 1173\u20131182.","journal-title":"Biology Open"},{"issue":"5","key":"9807_CR59","doi-asserted-by":"publisher","first-page":"e96372","DOI":"10.1371\/journal.pone.0096372","volume":"9","author":"M Fujita","year":"2014","unstructured":"Fujita, M., Takada, Y. K., & Takada, Y. (2014). The chemokine fractalkine can activate integrins without CX3CR1 through direct binding to a ligand-binding site distinct from the classical RGD-binding site. PLoS One, 9(5), e96372.","journal-title":"PLoS One"},{"issue":"44","key":"9807_CR60","doi-asserted-by":"publisher","first-page":"34183","DOI":"10.1074\/jbc.M005731200","volume":"275","author":"CA Haskell","year":"2000","unstructured":"Haskell, C. A., Cleary, M. D., & Charo, I. F. (2000). Unique role of the chemokine domain of fractalkine in cell capture. Kinetics of receptor dissociation correlate with cell adhesion. The Journal of Biological Chemistry, 275(44), 34183\u201334189.","journal-title":"The Journal of Biological Chemistry"},{"key":"9807_CR61","doi-asserted-by":"publisher","first-page":"2167","DOI":"10.1007\/s12035-016-9787-4","volume":"54","author":"\u0141A Poniatowski","year":"2017","unstructured":"Poniatowski, \u0141. A., Wojdasiewicz, P., Krawczyk, M., Szukiewicz, D., Gasik, R., Kubaszewski, \u0141., & Kurkowska-Jastrz\u0119bska, I. (2017). Analysis of the role of CX3CL1 (Fractalkine) and its receptor CX3CR1 in traumatic brain and spinal cord injury: Insight into recent advances in actions of neurochemokine agents. Molecular Neurobiology, 54, 2167\u20132188.","journal-title":"Molecular Neurobiology"},{"issue":"5","key":"9807_CR62","doi-asserted-by":"publisher","first-page":"2016","DOI":"10.4049\/jimmunol.1502376","volume":"197","author":"ZS Chheda","year":"2016","unstructured":"Chheda, Z. S., Sharma, R. K., Jala, V. R., Luster, A. D., & Haribabu, B. (2016). Chemoattractant receptors BLT1 and CXCR3 regulate antitumor immunity by facilitating CD8+ T cell migration into tumors. Journal of Immunology (Baltimore, Md. : 1950), 197(5), 2016\u20132026.","journal-title":"Journal of Immunology (Baltimore, Md. : 1950)"},{"key":"9807_CR63","doi-asserted-by":"publisher","first-page":"40","DOI":"10.1016\/j.ctrv.2017.11.007","volume":"63","author":"R Tokunaga","year":"2018","unstructured":"Tokunaga, R., Zhang, W., Naseem, M., Puccini, A., Berger, M. D., Soni, S., McSkane, M., Baba, H., & Lenz, H. J. (2018). CXCL9, CXCL10, CXCL11\/CXCR3 axis for immune activation \u2013 a target for novel cancer therapy. Cancer Treatment Reviews, 63, 40\u201347.","journal-title":"Cancer Treatment Reviews"},{"issue":"15","key":"9807_CR64","doi-asserted-by":"publisher","first-page":"7701","DOI":"10.1158\/0008-5472.CAN-06-0709","volume":"66","author":"TC Walser","year":"2006","unstructured":"Walser, T. C., Rifat, S., Ma, X., Kundu, N., Ward, C., Goloubeva, O., Johnson, M. G., Medina, J. C., Collins, T. L., & Fulton, A. M. (2006). Antagonism of CXCR3 inhibits lung metastasis in a murine model of metastatic breast cancer. Cancer Research, 66(15), 7701\u20137707.","journal-title":"Cancer Research"},{"issue":"32","key":"9807_CR65","doi-asserted-by":"publisher","first-page":"4679","DOI":"10.1038\/sj.onc.1210267","volume":"26","author":"K Kawada","year":"2007","unstructured":"Kawada, K., Hosogi, H., Sonoshita, M., Sakashita, H., Manabe, T., Shimahara, Y., Sakai, Y., Takabayashi, A., Oshima, M., & Taketo, M. M. (2007). Chemokine receptor CXCR3 promotes colon cancer metastasis to lymph nodes. Oncogene, 26(32), 4679\u20134688.","journal-title":"Oncogene"},{"issue":"11","key":"9807_CR66","doi-asserted-by":"publisher","first-page":"1755","DOI":"10.1038\/sj.bjc.6605078","volume":"100","author":"B Cambien","year":"2009","unstructured":"Cambien, B., Karimdjee, B. F., Richard-Fiardo, P., Bziouech, H., Barthel, R., Millet, M. A., Martini, V., Birnbaum, D., Scoazec, J. Y., Abello, J., Saati, T. A., Johnson, M. G., Sullivan, T. J., Medina, J. C., Collins, T. L., Schmid-Alliana, A., & Schmid-Antomarchi, H. (2009). Organ-specific inhibition of metastatic colon carcinoma by CXCR3 antagonism. British Journal of Cancer, 100(11), 1755\u20131764.","journal-title":"British Journal of Cancer"},{"issue":"3","key":"9807_CR67","doi-asserted-by":"publisher","first-page":"490","DOI":"10.1158\/1535-7163.MCT-08-0485","volume":"8","author":"X Ma","year":"2009","unstructured":"Ma, X., Norsworthy, K., Kundu, N., Rodgers, W. H., Gimotty, P. A., Goloubeva, O., Lipsky, M., Li, Y., Holt, D., & Fulton, A. (2009). CXCR3 expression is associated with poor survival in breast cancer and promotes metastasis in a murine model. Molecular Cancer Therapeutics, 8(3), 490\u2013498.","journal-title":"Molecular Cancer Therapeutics"},{"issue":"11","key":"9807_CR68","doi-asserted-by":"publisher","first-page":"2586","DOI":"10.1002\/ijc.24665","volume":"125","author":"E Pradelli","year":"2009","unstructured":"Pradelli, E., Karimdjee-Soilihi, B., Michiels, J. F., Ricci, J. E., Millet, M. A., Vandenbos, F., Sullivan, T. J., Collins, T. L., Johnson, M. G., Medina, J. C., Kleinerman, E. S., Schmid-Alliana, A., & Schmid-Antomarchi, H. (2009). Antagonism of chemokine receptor CXCR3 inhibits osteosarcoma metastasis to lungs. International Journal of Cancer, 125(11), 2586\u20132594.","journal-title":"International Journal of Cancer"},{"issue":"4","key":"9807_CR69","doi-asserted-by":"publisher","first-page":"1214","DOI":"10.1158\/0008-5472.CAN-10-3277","volume":"71","author":"K Kawada","year":"2011","unstructured":"Kawada, K., & Taketo, M. M. (2011). Significance and mechanism of lymph node metastasis in cancer progression. Cancer Research, 71(4), 1214\u20131218.","journal-title":"Cancer Research"},{"issue":"10","key":"9807_CR70","doi-asserted-by":"publisher","first-page":"533","DOI":"10.1007\/s00262-001-0231-9","volume":"50","author":"D Arenberg","year":"2001","unstructured":"Arenberg, D., White, E., Burdick, M., Strom, S., & Strieter, R. (2001). Improved survival in tumor-bearing SCID mice treated with interferon-\u03b3-inducible protein 10 (IP-10\/CXCL10). Cancer Immunology, Immunotherapy, 50(10), 533\u2013538.","journal-title":"Cancer Immunology, Immunotherapy"},{"issue":"3","key":"9807_CR71","doi-asserted-by":"publisher","first-page":"1456","DOI":"10.4049\/jimmunol.176.3.1456","volume":"176","author":"J Pan","year":"2006","unstructured":"Pan, J., Burdick, M. D., Belperio, J. A., Xue, Y. Y., Gerard, C., Sharma, S., et al. (2006). CXCR3\/CXCR3 ligand biological axis impairs RENCA tumor growth by a mechanism of immunoangiostasis. Journal of Immunology (Baltimore, Md. : 1950), 176(3), 1456\u20131464.","journal-title":"Journal of Immunology (Baltimore, Md. : 1950)"},{"issue":"6","key":"9807_CR72","doi-asserted-by":"publisher","first-page":"1434","DOI":"10.1189\/jlb.0306212","volume":"80","author":"X Yang","year":"2006","unstructured":"Yang, X., Chu, Y., Wang, Y., Zhang, R., & Xiong, S. (2006). Targeted in vivo expression of IFN-gamma-inducible protein 10 induces specific antitumor activity. Journal of Leukocyte Biology, 80(6), 1434\u20131444.","journal-title":"Journal of Leukocyte Biology"},{"issue":"4","key":"9807_CR73","doi-asserted-by":"publisher","first-page":"2278","DOI":"10.4049\/jimmunol.178.4.2278","volume":"178","author":"AV Gorbachev","year":"2007","unstructured":"Gorbachev, A. V., Kobayashi, H., Kudo, D., Tannenbaum, C. S., Finke, J. H., Shu, S., et al. (2007). CXC chemokine ligand 9\/monokine induced by IFN- production by tumor cells is critical for T cell-mediated suppression of cutaneous tumors. The Journal of Immunology, 178(4), 2278\u20132286.","journal-title":"The Journal of Immunology"},{"issue":"5","key":"9807_CR74","doi-asserted-by":"publisher","first-page":"2981","DOI":"10.18632\/oncotarget.3205","volume":"6","author":"TJ Zumwalt","year":"2015","unstructured":"Zumwalt, T. J., Arnold, M., Goel, A., & Boland, C. R. (2015). Active secretion of CXCL10 and CCL5 from colorectal cancer microenvironments associates with granzyme B+ CD8+ T-cell infiltration. Oncotarget, 6(5), 2981\u20132991.","journal-title":"Oncotarget"},{"issue":"3","key":"9807_CR75","doi-asserted-by":"publisher","first-page":"436","DOI":"10.1016\/j.ygyno.2017.03.007","volume":"145","author":"KK Au","year":"2017","unstructured":"Au, K. K., Peterson, N., Truesdell, P., Reid-Schachter, G., Khalaj, K., Ren, R., et al. (2017). CXCL10 alters the tumour immune microenvironment and disease progression in a syngeneic murine model of high-grade serous ovarian cancer. Gynecologic Oncology, 145(3), 436\u2013445.","journal-title":"Gynecologic Oncology"},{"issue":"1","key":"9807_CR76","doi-asserted-by":"publisher","first-page":"45","DOI":"10.1007\/s10549-008-0207-y","volume":"118","author":"K Specht","year":"2009","unstructured":"Specht, K., Harbeck, N., Smida, J., Annecke, K., Reich, U., Naehrig, J., Langer, R., Mages, J., Busch, R., Kruse, E., Klein-Hitpass, L., Schmitt, M., Kiechle, M., & Hoefler, H. (2009). Expression profiling identifies genes that predict recurrence of breast cancer after adjuvant CMF-based chemotherapy. Breast Cancer Research and Treatment, 118(1), 45\u201356.","journal-title":"Breast Cancer Research and Treatment"},{"issue":"1","key":"9807_CR77","doi-asserted-by":"publisher","first-page":"105","DOI":"10.1200\/JCO.2009.23.7370","volume":"28","author":"C Denkert","year":"2010","unstructured":"Denkert, C., Loibl, S., Noske, A., Roller, M., M\u00fcller, B. M., Komor, M., Budczies, J., Darb-Esfahani, S., Kronenwett, R., Hanusch, C., von T\u00f6rne, C., Weichert, W., Engels, K., Solbach, C., Schrader, I., Dietel, M., & von Minckwitz, G. (2010). Tumor-associated lymphocytes as an independent predictor of response to neoadjuvant chemotherapy in breast cancer. Journal of Clinical Oncology: Official Journal of the American Society of Clinical Oncology, 28(1), 105\u2013113.","journal-title":"Journal of Clinical Oncology: Official Journal of the American Society of Clinical Oncology"},{"issue":"4","key":"9807_CR78","doi-asserted-by":"publisher","first-page":"1429","DOI":"10.1053\/j.gastro.2009.10.057","volume":"138","author":"B Mlecnik","year":"2010","unstructured":"Mlecnik, B., Tosolini, M., Charoentong, P., Kirilovsky, A., Bindea, G., Berger, A., Camus, M., Gillard, M., Bruneval, P., Fridman, W.\u2013. H., Pag\u00e8s, F., Trajanoski, Z., & Galon, J. (2010). Biomolecular network reconstruction identifies T-cell homing factors associated with survival in colorectal cancer. Gastroenterology, 138(4), 1429\u20131440.","journal-title":"Gastroenterology"},{"issue":"9","key":"9807_CR79","doi-asserted-by":"publisher","first-page":"983","DOI":"10.1200\/JCO.2014.58.1967","volume":"33","author":"C Denkert","year":"2015","unstructured":"Denkert, C., von Minckwitz, G., Brase, J. C., Sinn, B. V., Gade, S., Kronenwett, R., et al. (2015). Tumor-infiltrating lymphocytes and response to neoadjuvant chemotherapy with or without carboplatin in human epidermal growth factor receptor 2-positive and triple-negative primary breast cancers. Journal of Clinical Oncology: Official Journal of the American Society of Clinical Oncology, 33(9), 983\u2013991.","journal-title":"Journal of Clinical Oncology: Official Journal of the American Society of Clinical Oncology"},{"issue":"5","key":"9807_CR80","doi-asserted-by":"publisher","first-page":"553","DOI":"10.1038\/bjc.2016.172","volume":"115","author":"H Bronger","year":"2016","unstructured":"Bronger, H., Singer, J., Windm\u00fcller, C., Reuning, U., Zech, D., Delbridge, C., Dorn, J., Kiechle, M., Schmalfeldt, B., Schmitt, M., & Avril, S. (2016). CXCL9 and CXCL10 predict survival and are regulated by cyclooxygenase inhibition in advanced serous ovarian cancer. British Journal of Cancer, 115(5), 553\u2013563.","journal-title":"British Journal of Cancer"},{"issue":"3","key":"9807_CR81","doi-asserted-by":"publisher","first-page":"936","DOI":"10.1245\/s10434-015-4909-1","volume":"23","author":"Y Sato","year":"2016","unstructured":"Sato, Y., Motoyama, S., Nanjo, H., Wakita, A., Yoshino, K., Sasaki, T., Nagaki, Y., Liu, J., Imai, K., Saito, H., & Minamiya, Y. (2016). CXCL10 expression status is prognostic in patients with advanced thoracic esophageal squamous cell carcinoma. Annals of Surgical Oncology, 23(3), 936\u2013942.","journal-title":"Annals of Surgical Oncology"},{"key":"9807_CR82","doi-asserted-by":"publisher","first-page":"8","DOI":"10.1016\/j.biopha.2015.12.021","volume":"78","author":"Z Wu","year":"2016","unstructured":"Wu, Z., Huang, X., Han, X., Li, Z., Zhu, Q., Yan, J., Yu, S., Jin, Z., Wang, Z., Zheng, Q., & Wang, Y. (2016). The chemokine CXCL9 expression is associated with better prognosis for colorectal carcinoma patients. Biomedicine & Pharmacotherapy, 78, 8\u201313.","journal-title":"Biomedicine & Pharmacotherapy"},{"issue":"4","key":"9807_CR83","doi-asserted-by":"publisher","first-page":"361","DOI":"10.1080\/08820139.2017.1280052","volume":"46","author":"Y Cao","year":"2017","unstructured":"Cao, Y., Huang, H., Wang, Z., & Zhang, G. (2017). The inflammatory CXC chemokines, GROalpha(high), IP-10(low), and MIG(low), in tumor microenvironment can be used as new indicators for non-small cell lung cancer progression. Immunological Investigations, 46(4), 361\u2013374.","journal-title":"Immunological Investigations"},{"issue":"6","key":"9807_CR84","doi-asserted-by":"publisher","first-page":"4224","DOI":"10.3892\/ol.2017.5994","volume":"13","author":"H Bronger","year":"2017","unstructured":"Bronger, H., Karge, A., Dreyer, T., Zech, D., Kraeft, S., Avril, S., Kiechle, M., & Schmitt, M. (2017). Induction of cathepsin B by the CXCR3 chemokines CXCL9 and CXCL10 in human breast cancer cells. Oncology Letters, 13(6), 4224\u20134230.","journal-title":"Oncology Letters"},{"issue":"5","key":"9807_CR85","doi-asserted-by":"publisher","first-page":"e331","DOI":"10.1038\/oncsis.2017.29","volume":"6","author":"C Windm\u00fcller","year":"2017","unstructured":"Windm\u00fcller, C., Zech, D., Avril, S., Boxberg, M., Dawidek, T., Schmalfeldt, B., Schmitt, M., Kiechle, M., & Bronger, H. (2017). CXCR3 mediates ascites-directed tumor cell migration and predicts poor outcome in ovarian cancer patients. Oncogenesis, 6(5), e331.","journal-title":"Oncogenesis"},{"issue":"17","key":"9807_CR86","doi-asserted-by":"publisher","first-page":"4351","DOI":"10.1158\/0008-5472.CAN-12-0579","volume":"72","author":"N Redjimi","year":"2012","unstructured":"Redjimi, N., Raffin, C., Raimbaud, I., Pignon, P., Matsuzaki, J., Odunsi, K., Valmori, D., & Ayyoub, M. (2012). CXCR3+ T regulatory cells selectively accumulate in human ovarian carcinomas to limit type I immunity. Cancer Research, 72(17), 4351\u20134360.","journal-title":"Cancer Research"},{"issue":"15","key":"9807_CR87","doi-asserted-by":"publisher","first-page":"4077","DOI":"10.1158\/1078-0432.CCR-17-0246","volume":"23","author":"C Wang","year":"2017","unstructured":"Wang, C., Armasu, S. M., Kalli, K. R., Maurer, M. J., Heinzen, E. P., Keeney, G. L., Cliby, W. A., Oberg, A. L., Kaufmann, S. H., & Goode, E. L. (2017). Pooled clustering of high-grade serous ovarian cancer gene expression leads to novel consensus subtypes associated with survival and surgical outcomes. Clinical Cancer Research, 23(15), 4077\u20134085.","journal-title":"Clinical Cancer Research"},{"issue":"7","key":"9807_CR88","doi-asserted-by":"publisher","first-page":"1755","DOI":"10.1016\/j.cell.2018.03.073","volume":"173","author":"AW Zhang","year":"2018","unstructured":"Zhang, A. W., McPherson, A., Milne, K., Kroeger, D. R., Hamilton, P. T., Miranda, A., Funnell, T., Little, N., de Souza, C. P. E., Laan, S., LeDoux, S., Cochrane, D. R., Lim, J. L. P., Yang, W., Roth, A., Smith, M. A., Ho, J., Tse, K., Zeng, T., Shlafman, I., Mayo, M. R., Moore, R., Failmezger, H., Heindl, A., Wang, Y. K., Bashashati, A., Grewal, D. S., Brown, S. D., Lai, D., Wan, A. N. C., Nielsen, C. B., Huebner, C., Tessier-Cloutier, B., Anglesio, M. S., Bouchard-C\u00f4t\u00e9, A., Yuan, Y., Wasserman, W. W., Gilks, C. B., Karnezis, A. N., Aparicio, S., McAlpine, J. N., Huntsman, D. G., Holt, R. A., Nelson, B. H., & Shah, S. P. (2018). Interfaces of malignant and immunologic clonal dynamics in ovarian cancer. Cell, 173(7), 1755\u20131769 e22.","journal-title":"Cell"},{"issue":"20","key":"9807_CR89","doi-asserted-by":"publisher","first-page":"5209","DOI":"10.1158\/0008-5472.CAN-12-1187","volume":"72","author":"W Peng","year":"2012","unstructured":"Peng, W., Liu, C., Xu, C., Lou, Y., Chen, J., Yang, Y., Yagita, H., Overwijk, W. W., Lizee, G., Radvanyi, L., & Hwu, P. (2012). PD-1 blockade enhances T-cell migration to tumors by elevating IFN-gamma inducible chemokines. Cancer Research, 72(20), 5209\u20135218.","journal-title":"Cancer Research"},{"issue":"7577","key":"9807_CR90","doi-asserted-by":"publisher","first-page":"249","DOI":"10.1038\/nature15520","volume":"527","author":"D Peng","year":"2015","unstructured":"Peng, D., Kryczek, I., Nagarsheth, N., Zhao, L., Wei, S., Wang, W., Sun, Y., Zhao, E., Vatan, L., Szeliga, W., Kotarski, J., Tarkowski, R., Dou, Y., Cho, K., Hensley-Alford, S., Munkarah, A., Liu, R., & Zou, W. (2015). Epigenetic silencing of TH1-type chemokines shapes tumour immunity and immunotherapy. Nature, 527(7577), 249\u2013253.","journal-title":"Nature"},{"issue":"6","key":"9807_CR91","doi-asserted-by":"publisher","first-page":"685","DOI":"10.1158\/2326-6066.CIR-17-0708","volume":"6","author":"H Seo","year":"2018","unstructured":"Seo, H., Kim, B. S., Bae, E. A., Min, B. S., Han, Y. D., Shin, S. J., & Kang, C. Y. (2018). IL21 therapy combined with PD-1 and Tim-3 blockade provides enhanced NK cell antitumor activity against MHC class I-deficient tumors. Cancer Immunology Research, 6(6), 685\u2013695.","journal-title":"Cancer Immunology Research"},{"key":"9807_CR92","doi-asserted-by":"publisher","first-page":"107","DOI":"10.1016\/j.lungcan.2019.03.020","volume":"132","author":"J Oyanagi","year":"2019","unstructured":"Oyanagi, J., Koh, Y., Sato, K., Mori, K., Teraoka, S., Akamatsu, H., Kanai, K., Hayata, A., Tokudome, N., Akamatsu, K., Nakanishi, M., Ueda, H., & Yamamoto, N. (2019). Predictive value of serum protein levels in patients with advanced non-small cell lung cancer treated with nivolumab. Lung Cancer, 132, 107\u2013113.","journal-title":"Lung Cancer"},{"issue":"7668","key":"9807_CR93","doi-asserted-by":"publisher","first-page":"471","DOI":"10.1038\/nature23465","volume":"548","author":"S Goel","year":"2017","unstructured":"Goel, S., DeCristo, M. J., Watt, A. C., BrinJones, H., Sceneay, J., Li, B. B., Khan, N., Ubellacker, J. M., Xie, S., Metzger-Filho, O., Hoog, J., Ellis, M. J., Ma, C. X., Ramm, S., Krop, I. E., Winer, E. P., Roberts, T. M., Kim, H. J., McAllister, S. S., & Zhao, J. J. (2017). CDK4\/6 inhibition triggers anti-tumour immunity. Nature, 548(7668), 471\u2013475.","journal-title":"Nature"},{"issue":"11","key":"9807_CR94","doi-asserted-by":"publisher","first-page":"2972","DOI":"10.1016\/j.celrep.2018.11.054","volume":"25","author":"L Ding","year":"2018","unstructured":"Ding, L., Kim, H. J., Wang, Q., Kearns, M., Jiang, T., Ohlson, C. E., Li, B. B., Xie, S., Liu, J. F., Stover, E. H., Howitt, B. E., Bronson, R. T., Lazo, S., Roberts, T. M., Freeman, G. J., Konstantinopoulos, P. A., Matulonis, U. A., & Zhao, J. J. (2018). PARP inhibition elicits STING-dependent antitumor immunity in Brca1-deficient ovarian cancer. Cell Reports, 25(11), 2972\u20132980 e5.","journal-title":"Cell Reports"},{"issue":"3","key":"9807_CR95","doi-asserted-by":"publisher","first-page":"1211","DOI":"10.1172\/JCI123319","volume":"129","author":"RM Chabanon","year":"2019","unstructured":"Chabanon, R. M., Muirhead, G., Krastev, D. B., Adam, J., Morel, D., Garrido, M., Lamb, A., H\u00e9non, C., Dorvault, N., Rouanne, M., Marlow, R., Bajrami, I., Carde\u00f1osa, M. L., Konde, A., Besse, B., Ashworth, A., Pettitt, S. J., Haider, S., Marabelle, A., Tutt, A. N. J., Soria, J. C., Lord, C. J., & Postel-Vinay, S. (2019). PARP inhibition enhances tumor cell-intrinsic immunity in ERCC1-deficient non-small cell lung cancer. The Journal of Clinical Investigation, 129(3), 1211\u20131228.","journal-title":"The Journal of Clinical Investigation"},{"issue":"6","key":"9807_CR96","doi-asserted-by":"publisher","first-page":"722","DOI":"10.1158\/2159-8290.CD-18-1218","volume":"9","author":"C Pantelidou","year":"2019","unstructured":"Pantelidou, C., Sonzogni, O., De Oliveria Taveira, M., Mehta, A. K., Kothari, A., Wang, D., et al. (2019). PARP inhibitor efficacy depends on CD8(+) T-cell recruitment via intratumoral STING pathway activation in BRCA-deficient models of triple-negative breast cancer. Cancer Discovery, 9(6), 722\u2013737.","journal-title":"Cancer Discovery"},{"issue":"5","key":"9807_CR97","doi-asserted-by":"publisher","first-page":"646","DOI":"10.1158\/2159-8290.CD-18-1020","volume":"9","author":"T Sen","year":"2019","unstructured":"Sen, T., Rodriguez, B. L., Chen, L., Corte, C. M. D., Morikawa, N., Fujimoto, J., Cristea, S., Nguyen, T., Diao, L., Li, L., Fan, Y., Yang, Y., Wang, J., Glisson, B. S., Wistuba, I. I., Sage, J., Heymach, J. V., Gibbons, D. L., & Byers, L. A. (2019). Targeting DNA damage response promotes antitumor immunity through STING-mediated T-cell activation in small cell lung cancer. Cancer Discovery, 9(5), 646\u2013661.","journal-title":"Cancer Discovery"},{"issue":"2","key":"9807_CR98","doi-asserted-by":"publisher","first-page":"311","DOI":"10.1158\/0008-5472.CAN-18-1003","volume":"79","author":"J Shen","year":"2019","unstructured":"Shen, J., Zhao, W., Ju, Z., Wang, L., Peng, Y., Labrie, M., Yap, T. A., Mills, G. B., & Peng, G. (2019). PARPi triggers the STING-dependent immune response and enhances the therapeutic efficacy of immune checkpoint blockade independent of BRCAness. Cancer Research, 79(2), 311\u2013319.","journal-title":"Cancer Research"},{"issue":"1","key":"9807_CR99","doi-asserted-by":"publisher","first-page":"1853","DOI":"10.1038\/s41598-019-38534-6","volume":"9","author":"Z Wang","year":"2019","unstructured":"Wang, Z., Sun, K., Xiao, Y., Feng, B., Mikule, K., Ma, X., Feng, N., Vellano, C. P., Federico, L., Marszalek, J. R., Mills, G. B., Hanke, J., Ramaswamy, S., & Wang, J. (2019). Niraparib activates interferon signaling and potentiates anti-PD-1 antibody efficacy in tumor models. Scientific Reports, 9(1), 1853.","journal-title":"Scientific Reports"},{"issue":"6","key":"9807_CR100","doi-asserted-by":"publisher","first-page":"945","DOI":"10.1093\/annonc\/mdl053","volume":"17","author":"F Andre","year":"2006","unstructured":"Andre, F., Cabioglu, N., Assi, H., Sabourin, J. C., Delaloge, S., Sahin, A., Broglio, K., Spano, J. P., Combadiere, C., Bucana, C., Soria, J. C., & Cristofanilli, M. (2006). Expression of chemokine receptors predicts the site of metastatic relapse in patients with axillary node positive primary breast cancer. Annals of Oncology, 17(6), 945\u2013951.","journal-title":"Annals of Oncology"},{"issue":"5","key":"9807_CR101","doi-asserted-by":"publisher","first-page":"R91","DOI":"10.1186\/bcr3016","volume":"13","author":"WL Jamieson-Gladney","year":"2011","unstructured":"Jamieson-Gladney, W. L., Zhang, Y., Fong, A. M., Meucci, O., & Fatatis, A. (2011). The chemokine receptor CX(3)CR1 is directly involved in the arrest of breast cancer cells to the skeleton. Breast Cancer Research, 13(5), R91.","journal-title":"Breast Cancer Research"},{"issue":"14","key":"9807_CR102","doi-asserted-by":"publisher","first-page":"4693","DOI":"10.1158\/0008-5472.CAN-03-3437","volume":"64","author":"SA Shulby","year":"2004","unstructured":"Shulby, S. A., Dolloff, N. G., Stearns, M. E., Meucci, O., & Fatatis, A. (2004). CX3CR1-fractalkine expression regulates cellular mechanisms involved in adhesion, migration, and survival of human prostate cancer cells. Cancer Research, 64(14), 4693\u20134698.","journal-title":"Cancer Research"},{"issue":"21","key":"9807_CR103","doi-asserted-by":"publisher","first-page":"9060","DOI":"10.1158\/0008-5472.CAN-08-1810","volume":"68","author":"F Marchesi","year":"2008","unstructured":"Marchesi, F., Piemonti, L., Fedele, G., Destro, A., Roncalli, M., Albarello, L., Doglioni, C., Anselmo, A., Doni, A., Bianchi, P., Laghi, L., Malesci, A., Cervo, L., Malosio, M. L., Reni, M., Zerbi, A., di Carlo, V., Mantovani, A., & Allavena, P. (2008). The chemokine receptor CX3CR1 is involved in the neural tropism and malignant behavior of pancreatic ductal adenocarcinoma. Cancer Research, 68(21), 9060\u20139069.","journal-title":"Cancer Research"},{"issue":"1","key":"9807_CR104","doi-asserted-by":"publisher","first-page":"77","DOI":"10.1016\/j.cytogfr.2009.11.001","volume":"21","author":"F Marchesi","year":"2010","unstructured":"Marchesi, F., Piemonti, L., Mantovani, A., & Allavena, P. (2010). Molecular mechanisms of perineural invasion, a forgotten pathway of dissemination and metastasis. Cytokine & Growth Factor Reviews, 21(1), 77\u201382.","journal-title":"Cytokine & Growth Factor Reviews"},{"issue":"1","key":"9807_CR105","doi-asserted-by":"publisher","first-page":"11","DOI":"10.1158\/1541-7786.MCR-11-0256","volume":"10","author":"M Kim","year":"2012","unstructured":"Kim, M., Rooper, L., Xie, J., Kajdacsy-Balla, A. A., & Barbolina, M. V. (2012). Fractalkine receptor CX(3)CR1 is expressed in epithelial ovarian carcinoma cells and required for motility and adhesion to peritoneal mesothelial cells. Molecular Cancer Research, 10(1), 11\u201324.","journal-title":"Molecular Cancer Research"},{"issue":"21","key":"9807_CR106","doi-asserted-by":"publisher","first-page":"3025","DOI":"10.1038\/onc.2016.456","volume":"36","author":"H Gurler Main","year":"2017","unstructured":"Gurler Main, H., Xie, J., Muralidhar, G. G., Elfituri, O., Xu, H., Kajdacsy-Balla, A. A., & Barbolina, M. V. (2017). Emergent role of the fractalkine axis in dissemination of peritoneal metastasis from epithelial ovarian carcinoma. Oncogene, 36(21), 3025\u20133036.","journal-title":"Oncogene"},{"issue":"9","key":"9807_CR107","doi-asserted-by":"publisher","first-page":"2013","DOI":"10.1002\/ijc.22908","volume":"121","author":"N Kanagawa","year":"2007","unstructured":"Kanagawa, N., Niwa, M., Hatanaka, Y., Tani, Y., Nakagawa, S., Fujita, T., Yamamoto, A., & Okada, N. (2007). CC-chemokine ligand 17 gene therapy induces tumor regression through augmentation of tumor-infiltrating immune cells in a murine model of preexisting CT26 colon carcinoma. International Journal of Cancer, 121(9), 2013\u20132022.","journal-title":"International Journal of Cancer"},{"issue":"4","key":"9807_CR108","doi-asserted-by":"publisher","first-page":"978","DOI":"10.1016\/j.bbrc.2007.10.124","volume":"364","author":"T Ren","year":"2007","unstructured":"Ren, T., Chen, Q., Tian, Z., & Wei, H. (2007). Down-regulation of surface fractalkine by RNA interference in B16 melanoma reduced tumor growth in mice. Biochemical and Biophysical Research Communications, 364(4), 978\u2013984.","journal-title":"Biochemical and Biophysical Research Communications"},{"issue":"16","key":"9807_CR109","doi-asserted-by":"publisher","first-page":"1226","DOI":"10.1038\/sj.gt.3302959","volume":"14","author":"L Tang","year":"2007","unstructured":"Tang, L., Hu, H., Hu, P., Lan, Y., Peng, M., Chen, M., et al. (2007). Gene therapy with CX3CL1\/fractalkine induces antitumor immunity to regress effectively mouse hepatocellular carcinoma. Gene Therapy, 14(16), 1226\u20131234.","journal-title":"Gene Therapy"},{"issue":"3","key":"9807_CR110","doi-asserted-by":"publisher","first-page":"365","DOI":"10.1136\/gut.2005.088989","volume":"56","author":"S Vitale","year":"2007","unstructured":"Vitale, S., Cambien, B., Karimdjee, B. F., Barthel, R., Staccini, P., Luci, C., Breittmayer, V., Anjuere, F., Schmid-Alliana, A., & Schmid-Antomarchi, H. (2007). Tissue-specific differential antitumour effect of molecular forms of fractalkine in a mouse model of metastatic colon cancer. Gut, 56(3), 365\u2013372.","journal-title":"Gut"},{"issue":"2","key":"9807_CR111","doi-asserted-by":"publisher","first-page":"316","DOI":"10.1002\/ijc.22660","volume":"121","author":"YRA Yu","year":"2007","unstructured":"Yu, Y. R. A., Fong, A. M., Combadiere, C., Gao, J. L., Murphy, P. M., & Patel, D. D. (2007). Defective antitumor responses in CX3CR1-deficient mice. International Journal of Cancer, 121(2), 316\u2013322.","journal-title":"International Journal of Cancer"},{"issue":"11","key":"9807_CR112","doi-asserted-by":"publisher","first-page":"761","DOI":"10.1038\/cgt.2011.42","volume":"18","author":"P Richard-Fiardo","year":"2011","unstructured":"Richard-Fiardo, P., Cambien, B., Pradelli, E., Beilvert, F., Pitard, B., Schmid-Antomarchi, H., & Schmid-Alliana, A. (2011). Effect of fractalkine-Fc delivery in experimental lung metastasis using DNA\/704 nanospheres. Cancer Gene Therapy, 18(11), 761\u2013772.","journal-title":"Cancer Gene Therapy"},{"issue":"9","key":"9807_CR113","doi-asserted-by":"publisher","first-page":"e25669","DOI":"10.4161\/onci.25669","volume":"2","author":"M Tard\u00e1guila","year":"2013","unstructured":"Tard\u00e1guila, M., & Ma\u00f1es, S. (2013). CX3CL1 at the crossroad of EGF signals: Relevance for the progression of ERBB2(+) breast carcinoma. Oncoimmunology, 2(9), e25669.","journal-title":"Oncoimmunology"},{"issue":"1","key":"9807_CR114","doi-asserted-by":"publisher","first-page":"227","DOI":"10.1182\/blood-2011-06-357442","volume":"119","author":"Y Lee","year":"2012","unstructured":"Lee, Y., Chittezhath, M., Andr\u00e9, V., Zhao, H., Poidinger, M., Biondi, A., et al. (2012). Protumoral role of monocytes in human B-cell precursor acute lymphoblastic leukemia: Involvement of the chemokine CXCL10. Blood, 119(1), 227\u2013237.","journal-title":"Blood"},{"issue":"40","key":"9807_CR115","doi-asserted-by":"publisher","first-page":"30731","DOI":"10.1074\/jbc.M110.128124","volume":"285","author":"SY Shin","year":"2010","unstructured":"Shin, S. Y., Nam, J. S., Lim, Y., & Lee, Y. H. (2010). TNF\u03b1-exposed bone marrow-derived mesenchymal stem cells promote locomotion of MDA-MB-231 breast cancer cells through transcriptional activation of CXCR3 ligand chemokines. Journal of Biological Chemistry, 285(40), 30731\u201330740.","journal-title":"Journal of Biological Chemistry"},{"issue":"7","key":"9807_CR116","doi-asserted-by":"publisher","first-page":"3396","DOI":"10.1158\/0008-5472.CAN-06-3087","volume":"67","author":"A Zipin-Roitman","year":"2007","unstructured":"Zipin-Roitman, A., Meshel, T., Sagi-Assif, O., Shalmon, B., Avivi, C., Pfeffer, R. M., Witz, I. P., & Ben-Baruch, A. (2007). CXCL10 promotes invasion-related properties in human colorectal carcinoma cells. Cancer Research, 67(7), 3396\u20133405.","journal-title":"Cancer Research"},{"issue":"2","key":"9807_CR117","doi-asserted-by":"publisher","first-page":"221","DOI":"10.1016\/j.canlet.2003.10.036","volume":"207","author":"A Pellegrino","year":"2004","unstructured":"Pellegrino, A., Antonaci, F., Russo, F., Merchionne, F., Ribatti, D., Vacca, A., et al. (2004). CXCR3-binding chemokines in multiple myeloma. Cancer Letters, 207(2), 221\u2013227.","journal-title":"Cancer Letters"},{"key":"9807_CR118","doi-asserted-by":"publisher","first-page":"479","DOI":"10.1016\/j.biopha.2016.04.069","volume":"82","author":"H Zhou","year":"2016","unstructured":"Zhou, H., Wu, J., Wang, T., Zhang, X., & Liu, D. (2016). CXCL10\/CXCR3 axis promotes the invasion of gastric cancer via PI3K\/AKT pathway-dependent MMPs production. Biomedicine & Pharmacotherapy = Biomedecine & Pharmacotherapie, 82, 479\u2013488.","journal-title":"Biomedicine & Pharmacotherapy = Biomedecine & Pharmacotherapie"},{"issue":"3","key":"9807_CR119","doi-asserted-by":"publisher","first-page":"889","DOI":"10.1016\/j.bbrc.2003.09.098","volume":"310","author":"PE Van den Steen","year":"2003","unstructured":"Van den Steen, P. E., Husson, S. J., Proost, P., Van Damme, J., & Opdenakker, G. (2003). Carboxyterminal cleavage of the chemokines MIG and IP-10 by gelatinase B and neutrophil collagenase. Biochemical and Biophysical Research Communications, 310(3), 889\u2013896.","journal-title":"Biochemical and Biophysical Research Communications"},{"issue":"28","key":"9807_CR120","doi-asserted-by":"publisher","first-page":"19389","DOI":"10.1074\/jbc.M800266200","volume":"283","author":"JH Cox","year":"2008","unstructured":"Cox, J. H., Dean, R. A., Roberts, C. R., & Overall, C. M. (2008). Matrix metalloproteinase processing of CXCL11\/I-TAC results in loss of chemoattractant activity and altered glycosaminoglycan binding. The Journal of Biological Chemistry, 283(28), 19389\u201319399.","journal-title":"The Journal of Biological Chemistry"},{"issue":"2","key":"9807_CR121","doi-asserted-by":"publisher","first-page":"122","DOI":"10.1016\/j.cellimm.2003.09.010","volume":"225","author":"LA Robinson","year":"2003","unstructured":"Robinson, L. A., Nataraj, C., Thomas, D. W., Cosby, J. M., Griffiths, R., Bautch, V. L., Patel, D. D., & Coffman, T. M. (2003). The chemokine CX3CL1 regulates NK cell activity in vivo. Cellular Immunology, 225(2), 122\u2013130.","journal-title":"Cellular Immunology"},{"issue":"22","key":"9807_CR122","doi-asserted-by":"publisher","first-page":"13800","DOI":"10.1074\/jbc.M115.638395","volume":"290","author":"U Repnik","year":"2015","unstructured":"Repnik, U., Starr, A. E., Overall, C. M., & Turk, B. (2015). Cysteine cathepsins activate ELR chemokines and inactivate non-ELR chemokines. The Journal of Biological Chemistry, 290(22), 13800\u201313811.","journal-title":"The Journal of Biological Chemistry"},{"issue":"13","key":"9807_CR123","doi-asserted-by":"publisher","first-page":"3554","DOI":"10.1182\/blood.V98.13.3554","volume":"98","author":"P Proost","year":"2001","unstructured":"Proost, P., Schutyser, E., Menten, P., Struyf, S., Wuyts, A., Opdenakker, G., et al. (2001). Amino-terminal truncation of CXCR3 agonists impairs receptor signaling and lymphocyte chemotaxis, while preserving antiangiogenic properties. Blood, 98(13), 3554\u20133561.","journal-title":"Blood"},{"issue":"5","key":"9807_CR124","doi-asserted-by":"publisher","first-page":"1301","DOI":"10.1084\/jem.182.5.1301","volume":"182","author":"F Liao","year":"1995","unstructured":"Liao, F. (1995). Human Mig chemokine: biochemical and functional characterization. Journal of Experimental Medicine, 182(5), 1301\u20131314.","journal-title":"Journal of Experimental Medicine"},{"key":"9807_CR125","doi-asserted-by":"publisher","first-page":"13402","DOI":"10.1074\/jbc.M312814200","volume":"279","author":"PJ Hensbergen","year":"2004","unstructured":"Hensbergen, P. J., Verzijl, D., Balog, C. I. A., Dijkman, R., van der Schors, R. C., van der Raaij-Helmer, E. M. H., van der Plas, M. J. A., Leurs, R., Deelder, A. M., Smit, M. J., & Tensen, C. P. (2004). Furin is a chemokine-modifying enzyme. Journal of Biological Chemistry, 279, 13402\u201313411.","journal-title":"Journal of Biological Chemistry"},{"issue":"1","key":"9807_CR126","doi-asserted-by":"crossref","first-page":"183","DOI":"10.1189\/jlb.72.1.183","volume":"72","author":"A Ludwig","year":"2002","unstructured":"Ludwig, A., Schiemann, F., Mentlein, R., Lindner, B., & Brandt, E. (2002). Dipeptidyl peptidase IV (CD26) on T cells cleaves the CXC chemokine CXCL11 (I-TAC) and abolishes the stimulating but not the desensitizing potential of the chemokine. Journal of Leukocyte Biology, 72(1), 183\u2013191.","journal-title":"Journal of Leukocyte Biology"},{"issue":"5","key":"9807_CR127","doi-asserted-by":"publisher","first-page":"1522","DOI":"10.1002\/art.21007","volume":"52","author":"A Inoue","year":"2005","unstructured":"Inoue, A., Hasegawa, H., Kohno, M., Ito, M. R., Terada, M., Imai, T., Yoshie, O., Nose, M., & Fujita, S. (2005). Antagonist of fractalkine (CX3CL1) delays the initiation and ameliorates the progression of lupus nephritis in MRL\/lpr mice. Arthritis and Rheumatism, 52(5), 1522\u20131533.","journal-title":"Arthritis and Rheumatism"},{"issue":"14","key":"9807_CR128","doi-asserted-by":"publisher","first-page":"13402","DOI":"10.1074\/jbc.M312814200","volume":"279","author":"PJ Hensbergen","year":"2004","unstructured":"Hensbergen, P. J., Verzijl, D., Balog, C. I. A., Dijkman, R., van der Schors, R. C., van der Raaij-Helmer, E. M. H., van der Plas, M. J. A., Leurs, R., Deelder, A. M., Smit, M. J., & Tensen, C. P. (2004). Furin is a chemokine-modifying enzyme: in vitro and in vivo processing of CXCL10 generates a C-terminally truncated chemokine retaining full activity. The Journal of Biological Chemistry, 279(14), 13402\u201313411.","journal-title":"The Journal of Biological Chemistry"},{"issue":"6","key":"9807_CR129","doi-asserted-by":"publisher","first-page":"679","DOI":"10.15252\/emmm.201506145","volume":"8","author":"J Decalf","year":"2016","unstructured":"Decalf, J., Tarbell, K. V., Casrouge, A., Price, J. D., Linder, G., Mottez, E., et al. (2016). Inhibition of DPP4 activity in humans establishes its in vivo role in CXCL10 post-translational modification: Prospective placebo-controlled clinical studies. EMBO Molecular Medicine, 8(6), 679\u2013683.","journal-title":"EMBO Molecular Medicine"},{"issue":"5","key":"9807_CR130","doi-asserted-by":"publisher","first-page":"819","DOI":"10.1016\/j.febslet.2008.02.005","volume":"582","author":"K Ajami","year":"2008","unstructured":"Ajami, K., Pitman, M. R., Wilson, C. H., Park, J., Menz, R. I., Starr, A. E., Cox, J. H., Abbott, C. A., Overall, C. M., & Gorrell, M. D. (2008). Stromal cell-derived factors 1alpha and 1beta, inflammatory protein-10 and interferon-inducible T cell chemo-attractant are novel substrates of dipeptidyl peptidase 8. FEBS Letters, 582(5), 819\u2013825.","journal-title":"FEBS Letters"},{"key":"9807_CR131","doi-asserted-by":"publisher","first-page":"3737","DOI":"10.1111\/febs.13371","volume":"282","author":"H Zhang","year":"2015","unstructured":"Zhang, H., Maqsudi, S., Rainczuk, A., Duffield, N., Lawrence, J., Keane, F. M., Justa-Schuch, D., Geiss-Friedlander, R., Gorrell, M. D., & Stephens, A. N. (2015). Identification of novel dipeptidyl peptidase 9 substrates by two-dimensional differential in-gel electrophoresis. FEBS Journal, 282, 3737\u20133757.","journal-title":"FEBS Journal"},{"issue":"1","key":"9807_CR132","doi-asserted-by":"publisher","first-page":"37","DOI":"10.1182\/blood-2006-10-049072","volume":"110","author":"P Proost","year":"2007","unstructured":"Proost, P., Mortier, A., Loos, T., Vandercappellen, J., Gouwy, M., Ronsse, I., Schutyser, E., Put, W., Parmentier, M., Struyf, S., & van Damme, J. (2007). Proteolytic processing of CXCL11 by CD13\/aminopeptidase N impairs CXCR3 and CXCR7 binding and signaling and reduces lymphocyte and endothelial cell migration. Blood, 110(1), 37\u201344.","journal-title":"Blood"},{"issue":"12","key":"9807_CR133","doi-asserted-by":"publisher","first-page":"8064","DOI":"10.4049\/jimmunol.178.12.8064","volume":"178","author":"C Hundhausen","year":"2007","unstructured":"Hundhausen, C., Schulte, A., Schulz, B., Andrzejewski, M. G., Schwarz, N., von Hundelshausen, P., et al. (2007). Regulated shedding of transmembrane chemokines by the disintegrin and metalloproteinase 10 facilitates detachment of adherent leukocytes. Journal of Immunology (Baltimore, Md. : 1950), 178(12), 8064\u20138072.","journal-title":"Journal of Immunology (Baltimore, Md. : 1950)"},{"issue":"41","key":"9807_CR134","doi-asserted-by":"crossref","first-page":"37993","DOI":"10.1074\/jbc.M106434200","volume":"276","author":"KJ Garton","year":"2001","unstructured":"Garton, K. J., Gough, P. J., Blobel, C. P., Murphy, G., Greaves, D. R., Dempsey, P. J., et al. (2001). Tumor necrosis factor-alpha-converting enzyme (ADAM17) mediates the cleavage and shedding of fractalkine (CX3CL1). The Journal of Biological Chemistry, 276(41), 37993\u201338001.","journal-title":"The Journal of Biological Chemistry"},{"issue":"5","key":"9807_CR135","doi-asserted-by":"publisher","first-page":"694","DOI":"10.1160\/TH07-01-0035","volume":"97","author":"A Ludwig","year":"2007","unstructured":"Ludwig, A., & Weber, C. (2007). Transmembrane chemokines: versatile \u201cspecial agents\u201d in vascular inflammation. Thrombosis and Haemostasis, 97(5), 694\u2013703.","journal-title":"Thrombosis and Haemostasis"},{"issue":"Pt 22","key":"9807_CR136","doi-asserted-by":"publisher","first-page":"5259","DOI":"10.1242\/jcs.135343","volume":"126","author":"LA Johnson","year":"2013","unstructured":"Johnson, L. A., & Jackson, D. G. (2013). The chemokine CX3CL1 promotes trafficking of dendritic cells through inflamed lymphatics. Journal of Cell Science, 126(Pt 22), 5259\u20135270.","journal-title":"Journal of Cell Science"},{"issue":"8a","key":"9807_CR137","doi-asserted-by":"publisher","first-page":"1526","DOI":"10.1111\/j.1582-4934.2009.00787.x","volume":"13","author":"K Bourd-Boittin","year":"2009","unstructured":"Bourd-Boittin, K., Basset, L., Bonnier, D., L\u2019Helgoualc\u2019h, A., Samson, M., & Th\u00e9ret, N. (2009). CX3CL1\/fractalkine shedding by human hepatic stellate cells: Contribution to chronic inflammation in the liver. Journal of Cellular and Molecular Medicine, 13(8a), 1526\u20131535.","journal-title":"Journal of Cellular and Molecular Medicine"},{"issue":"2","key":"9807_CR138","doi-asserted-by":"publisher","first-page":"283","DOI":"10.1016\/j.expneurol.2011.09.012","volume":"234","author":"M Malcangio","year":"2012","unstructured":"Malcangio, M., & Clark, A. K. (2012). Microglial signalling mechanisms: cathepsin S and fractalkine. Experimental Neurology, 234(2), 283\u2013292.","journal-title":"Experimental Neurology"},{"issue":"3","key":"9807_CR139","doi-asserted-by":"publisher","first-page":"R69","DOI":"10.1186\/ar2441","volume":"10","author":"ME Wildenberg","year":"2008","unstructured":"Wildenberg, M. E., van Helden-Meeuwsen, C. G., Drexhage, H. A., & Versnel, M. A. (2008). Altered fractalkine cleavage potentially promotes local inflammation in NOD salivary gland. Arthritis Research and Therapy, 10(3), R69.","journal-title":"Arthritis Research and Therapy"},{"issue":"11","key":"9807_CR140","doi-asserted-by":"publisher","first-page":"e0207255","DOI":"10.1371\/journal.pone.0207255","volume":"13","author":"V Juric","year":"2018","unstructured":"Juric, V., O\u2019Sullivan, C., Stefanutti, E., Kovalenko, M., Greenstein, A., Barry-Hamilton, V., et al. (2018). MMP-9 inhibition promotes anti-tumor immunity through disruption of biochemical and physical barriers to T-cell trafficking to tumors. PLoS One, 13(11), e0207255.","journal-title":"PLoS One"},{"issue":"1","key":"9807_CR141","doi-asserted-by":"publisher","first-page":"115","DOI":"10.1016\/j.jcmgh.2018.08.008","volume":"7","author":"S Nishina","year":"2019","unstructured":"Nishina, S., Yamauchi, A., Kawaguchi, T., Kaku, K., Goto, M., Sasaki, K., Hara, Y., Tomiyama, Y., Kuribayashi, F., Torimura, T., & Hino, K. (2019). Dipeptidyl peptidase 4 inhibitors reduce hepatocellular carcinoma by activating lymphocyte chemotaxis in mice. Cellular and Molecular Gastroenterology and Hepatology, 7(1), 115\u2013134.","journal-title":"Cellular and Molecular Gastroenterology and Hepatology"},{"issue":"3","key":"9807_CR142","doi-asserted-by":"publisher","first-page":"257","DOI":"10.1038\/s41590-019-0321-5","volume":"20","author":"C Hollande","year":"2019","unstructured":"Hollande, C., Boussier, J., Ziai, J., Nozawa, T., Bondet, V., Phung, W., Lu, B., Duffy, D., Paradis, V., Mallet, V., Eberl, G., Sandoval, W., Schartner, J. M., Pol, S., Barreira da Silva, R., & Albert, M. L. (2019). Inhibition of the dipeptidyl peptidase DPP4 (CD26) reveals IL-33-dependent eosinophil-mediated control of tumor growth. Nature Immunology, 20(3), 257\u2013264.","journal-title":"Nature Immunology"},{"issue":"3","key":"9807_CR143","doi-asserted-by":"publisher","first-page":"530","DOI":"10.1002\/ijc.28393","volume":"134","author":"A Rainczuk","year":"2014","unstructured":"Rainczuk, A., Rao, J. R., Gathercole, J. L., Fairweather, N. J., Chu, S., Masadah, R., Jobling, T. W., Deb-Choudhury, S., Dyer, J., & Stephens, A. N. (2014). Evidence for the antagonistic form of CXC-motif chemokine CXCL10 in serous epithelial ovarian tumours. International Journal of Cancer, 134(3), 530\u2013541.","journal-title":"International Journal of Cancer"}],"container-title":["Cancer and Metastasis Reviews"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s10555-019-09807-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s10555-019-09807-3\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s10555-019-09807-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,9,19]],"date-time":"2023-09-19T19:37:09Z","timestamp":1695152229000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s10555-019-09807-3"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,9]]},"references-count":143,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2019,9]]}},"alternative-id":["9807"],"URL":"https:\/\/doi.org\/10.1007\/s10555-019-09807-3","relation":{},"ISSN":["0167-7659","1573-7233"],"issn-type":[{"value":"0167-7659","type":"print"},{"value":"1573-7233","type":"electronic"}],"subject":[],"published":{"date-parts":[[2019,9]]},"assertion":[{"value":"3 September 2019","order":1,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Compliance with ethical standards"}},{"value":"The authors declare that they have no conflict of interest.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}}]}}